Introduction
============

Stroke, of which \~85% are ischemic, is a common cerebrovascular disease that poses a major challenge to human health worldwide ([@b1-mmr-22-04-3081],[@b2-mmr-22-04-3081]). It is estimated that 16.9 million individuals suffer a stroke every year, and \~6 million of these culminate in death, whereas three out of four survivors suffer from permanent disabilities, including motor and cognitive impairments ([@b1-mmr-22-04-3081],[@b2-mmr-22-04-3081]). The occurrence of these unfavorable outcomes may be attributed to the delay in the diagnosis, and the lack of effective treatments available. Thus, in addition to conventional clinical examinations, imaging evaluation and endovascular therapy ([@b3-mmr-22-04-3081],[@b4-mmr-22-04-3081]), there is an urgent need to explore novel targets for the diagnosis and treatment of acute ischemic stroke (AIS).

Long non-coding RNAs (lncRNAs), are non-coding RNAs of \>200 nucleotides in length that serve important roles in various diseases, such as coronary artery disease, diabetes and cancer ([@b5-mmr-22-04-3081]), and thus, they may represent potential biomarkers for the diagnosis and treatment of AIS. This hypothesis has been validated by numerous previous studies; for example, Zhu *et al* ([@b6-mmr-22-04-3081]) identified that the expression levels of the lncRNA, myocardial infarction-associated transcript (MIAT), were significantly upregulated in blood samples compared with control samples, in addition to demonstrating that MIAT may serve as a potential diagnostic and prognostic indicator for patients with AIS \[area under the curve (AUC), 0.842; sensitivity, 74.1%; specificity, 80.4%\] and prognostic (AUC, 0.791; sensitivity, 79.2%; specificity, 72.9%). Feng *et al* ([@b7-mmr-22-04-3081]) reported that plasma expression levels of the lncRNA, antisense non-coding RNA in the INK4 locus (ANRIL), were lower in patients with AIS compared with control samples, with a prediction value for AIS risk of 0.759, and that ANRIL expression also negatively correlated with the National Institutes of Health Stroke Scale (NIHSS) score. In addition, using a lncRNA microarray, Deng *et al* ([@b8-mmr-22-04-3081]) screened a three-lncRNA signature \[long intergenic non-coding RNA (linc)-DHFRL1-4, small nucleolar RNA host gene 15, and family with sequence similarity 98, member A)\], and discovered that this lncRNA-based combination index distinguished patients with AIS from healthy controls, with an AUC \>0.84. However, circulating AIS-related lncRNAs still require further investigation.

Accumulating evidence indicates that lncRNAs may be involved in the development of diseases by acting as competing endogenous RNAs (ceRNAs) for microRNA (miRNAs), which are non-coding RNAs of \~20 nucleotides in length that negatively regulate target gene expression at the post-transcriptional level ([@b9-mmr-22-04-3081]). Thus, investigating the lncRNA-related ceRNA axis may provide novel biomarker candidates for AIS; for example, the recent discoveries of ENST00000568297, ENST00000568243, NR_046084, CCAAT/enhancer binding protein, a antisense (AS) RNA 1, lincRNA 884, and matrilin-1-AS RNA 1 ([@b10-mmr-22-04-3081],[@b11-mmr-22-04-3081]). However, the interacting miRNAs and protein-coding mRNAs in these two studies are not differentially expressed. Therefore, an additional differentially expressed lncRNAs (DELs)/miRNAs (DEMs)/genes (DEGs) network should be constructed to identify potential AIS-associated ceRNA axes. In the present study, mRNA, lncRNA and miRNA expression profiles from AIS samples and healthy samples were collected from the Gene Expression Omnibus (GEO) repository, and were used to establish lncRNA-related ceRNA networks in AIS. The interactions amongst lncRNAs, miRNAs, and genes may provide a novel and valuable insight into understanding the pathogenesis of AIS, and may present novel biomarkers, or targets, for the diagnosis and treatment of AIS.

Materials and methods
=====================

### Data collection

Five high-throughput datasets, including 4 miRNA (GSE110993, GSE95204, GSE86291 and GSE55937) and 1 mRNA (GSE16561) expression profile, of AIS were obtained from the GEO database (<http://www.ncbi.nlm.nih.gov/geo>). Twenty patients with AIS and 20 matched healthy controls were collected from the GSE110993 dataset, and the circulating miRNAs were examined by high-throughput sequencing using Illumina HiScanSQ (Illumina, Inc.; platform, GPL15456) ([@b12-mmr-22-04-3081]). Three patients with AIS and three matched healthy controls were obtained from the GEO database dataset, GSE95204, to detect plasma miRNA expression profiles using the Exiqon miRCURY LNA™ microRNA array system (miRBase; condensed Probe_ID version; version 18; Exiqon, Qiagen). Plasma samples from seven patients with AIS and four matched healthy controls were obtained from the GSE86291 dataset to screen for miRNA biomarkers using the Agilent-046064 Unrestricted_Human_miRNA_V19.0_Microarray (accession no. GPL18402) ([@b13-mmr-22-04-3081]). Using the GSE55937 dataset, miRNA expression was determined in the peripheral blood of 24 patients with AIS and 24 controls using the Affymetrix Multispecies miRNA-3 Array (Affymetrix; Thermo Fisher Scientific, Inc.; accession no. GPL16384) ([@b14-mmr-22-04-3081]). Using the GSE16561 dataset, mRNA and lncRNA expression profiles were analyzed in the peripheral whole blood of 39 patients with AIS and 24 matched healthy controls using the Illumina HumanRef-8 version 3.0 expression beadchip (Illumina, Inc.; platform, GPL6883).

### Dataset preprocessing and differential expression analysis

The raw data were downloaded from the GEO database. For the microarray datasets, the data were quantile-normalized, and the DEGs, DELs and DEMs were identified using the linear models for microarray data (limma) software package (version 3.34.0; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>) ([@b15-mmr-22-04-3081]) in R Bioconductor (version 3.4.1; <http://www.R-project.org>). To sequence the dataset, fastp software (version 1.0; <http://github.com/OpenGene/fastp>) was used to perform the adapter trimming and quality control ([@b16-mmr-22-04-3081]), and the DEMs were subsequently screened using DESeq2 (version 1.16.1; <http://bioconductor.org/packages/3.5/bioc/html/DESeq2.html>) ([@b17-mmr-22-04-3081]). P\<0.05 was defined as the statistical threshold for DEMs to obtain overlap among different datasets. P\<0.05 and log~2~fold change (FC) \>0.33 were defined as the statistical cut-off values for DEGs and DELs. A Venn diagram was created to determine DEMs shared between any two datasets using Draw Venn Diagram online tool (version 1.0; <http://bioinformatics.psb.ugent.be/webtools/Venn>). Hierarchical clustering was performed using the pheatmap package (version 1.0.8; <http://cran.r-project.org/web/packages/pheatmap>) to determine the intersection between differentially expressed RNAs in different samples.

### Functional enrichment analysis

The clusterProfiler tool (version 3.2.11; <http://www.bioconductor.org/packages/release/bioc/html/clusterProfiler.html>) was used to analyze the potential functions of DEGs, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Adjusted P\<0.05 was set as the criterion.

### Protein-protein interaction (PPI) network

PPI data of DEGs were collected from the Search Tool for the Retrieval of Interacting Genes (STRING) database (version 10.0; <http://string-db.org>) ([@b18-mmr-22-04-3081]). Interactions with a combined score of \>700 were used to construct the PPI network. Several topological features of the nodes (proteins) in the PPI network were calculated using the CytoNCA plugin (version 2.1.6; <http://apps.cytoscape.org/apps/cytonca>) ([@b19-mmr-22-04-3081]) in Cytoscape software (version 3.0; <http://cytoscape.org>), to identify hub genes, including degree, betweenness and closeness centrality. The Molecular Complex Detection (MCODE; version 1.4.2; <http://apps.cytoscape.org/apps/mcode>) plugin of the Cytoscape software was used to extract highly interconnected sub-networks, with a MCODE score of \>6 and number of nodes \>6 set as the threshold values ([@b20-mmr-22-04-3081]).

### Determining the overall ceRNA regulatory network

The miRcode (version 1.0; <http://www.mircode.org>) ([@b21-mmr-22-04-3081]), starBase (version 2.0; <http://starbase.sysu.edu.cn/starbase2>) ([@b22-mmr-22-04-3081]), DIANA-LncBase (version 2.0; <http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=lncbasev2/index-predicted>) ([@b23-mmr-22-04-3081]), and miRwalk (version 2.0; zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2) ([@b24-mmr-22-04-3081]) databases were used to predict the miRNAs interacting with DELs, which were subsequently intersected with the DEMs shared between two datasets to obtain DEL/DEM interaction pairs. The target genes of the crosstalk between the DEMs and DEGs were predicted using the miRwalk database ([@b24-mmr-22-04-3081]). The DEL/DEM and DEM/DEG interactors were subsequently linked to construct the ceRNA network using the Cytoscape software.

### Determining potential AIS-relevant ceRNA networks

The AIS-related KEGG pathways were downloaded from the Comparative Toxicogenomics Database (CTD; version 1.0; <http://ctdbase.org>) and were subsequently overlapped with the pathways enriched by the DEGs in the overall ceRNA network. The ceRNA network, including the pathway-related DEGs, was extracted individually to define a potential AIS-related ceRNA network. Known lncRNAs were collected from the LncRNADisease database (version 2.0; <http://www.cuilab.cn/lncrnadisease>) to determine whether the DELs identified in the AIS-related ceRNA network were novel.

Results
=======

### DEGs and DELs analyses

Based on the microarray data analysis between patients with AIS and healthy controls using the limma method, 2,041 DEGs were screened from the GSE16561 dataset. A total of 1,337 DEGs were found to be upregulated, such as paxillin (PXN), ras homolog family member A (RHOA), STAT1, and growth factor receptor bound protein 2 (GRB2), and 704 downregulated, including FYN proto-oncogene, Src family tyrosine kinase (FYN) ([Table I](#tI-mmr-22-04-3081){ref-type="table"}). In addition, two upregulated DELs \[human leukocyte antigen complex group 27 (HCG27), and inositol-tetrakisphosphate 1-kinase AS RNA 1 (ITPK1-AS1)\] and three downregulated DELs \[minichromosome maintenance complex component 3 associated protein-antisense RNA 1 (MCM3AP-AS1), leucine rich repeat containing 37 member A4 (LRRC37A4P), and lincRNA 1089 (LINC01089)\] were identified ([Table I](#tI-mmr-22-04-3081){ref-type="table"}). The heatmap revealed that the differentially expressed RNAs identified from this dataset could distinguish the AIS samples from the healthy controls ([Fig. 1](#f1-mmr-22-04-3081){ref-type="fig"}).

### DEMs analysis

The microarray data analysis between AIS samples and healthy controls revealed 104 DEMs in the GSE95204 dataset (39 upregulated; 65 downregulated), 74 DEMs in the GSE86291 dataset (29 upregulated; 45 downregulated), and 111 DEMs in the GSE55937 dataset (77 upregulated; 32 downregulated) ([Table I](#tI-mmr-22-04-3081){ref-type="table"}). Sequence analysis between AIS samples and healthy controls using the DESeq2 method identified 120 DEMs in the GSE110993 dataset, 22 that were upregulated, and 98 that were downregulated. Venn diagram analysis demonstrated that 10 DEMs were shared between at least two of the four miRNA expression profile datasets ([Table I](#tI-mmr-22-04-3081){ref-type="table"}), including: Five downregulated miRNAs; hsa-miRNA (miR)-345-5p, hsa-miR-19a, hsa-let-7i, hsa-miR-5100 and hsa-miR-4667-5p ([Fig. 2A](#f2-mmr-22-04-3081){ref-type="fig"}); and five upregulated miRNAs; hsa-miR-1283, hsa-miR-99b, hsa-miR-125a, hsa-miR-1263 and hsa-miR-551a ([Fig. 2B](#f2-mmr-22-04-3081){ref-type="fig"}).

### Functional enrichment analysis of the DEGs

Functional enrichment analysis of all the DEGs revealed that the DEGs were enriched in 921 GO biological processes and 56 significant KEGG pathways. Among them, inflammatory-related functions, such as 'I-κB kinase/NF-κB signaling'/'NF-κB signaling pathway', 'T cell differentiation'/'Th17 cell differentiation'/'Th1 and Th2 cell differentiation', 'T cell activation'/'T cell receptor signaling pathway', were the most significant, and were identified by both GO and KEGG enrichment analyses ([Fig. 3](#f3-mmr-22-04-3081){ref-type="fig"}). Thus, this indicated that inflammatory genes may be crucial for AIS development.

### PPI network of DEGs

Using the STRING database, a total of 6,246 PPI interaction pairs were predicted from the 1,235 DEGs used to construct the PPI network (data not shown). Twenty genes were identified as hub genes because they ranked in the top 60 (5% of all DEGs), according to the ranking results of all three topological features ([Table II](#tII-mmr-22-04-3081){ref-type="table"}). Furthermore, seven significant modules were extracted from the PPI network, in which the hub genes, PXN, FYN, RHOA, STAT1 and GRB2 were enriched in module 7 ([Fig. 4](#f4-mmr-22-04-3081){ref-type="fig"}; [Table III](#tIII-mmr-22-04-3081){ref-type="table"}). Functional analysis revealed that the genes in module 7 may be involved in AIS by participating in 78 significant KEGG pathways ([Table IV](#tIV-mmr-22-04-3081){ref-type="table"}), 61 of which included at least one of these five hub genes; T cell receptor signaling pathway (GRB2/FYN/RHOA), chemokine signaling pathway (PXN/GRB2/STAT1/RHOA), focal adhesion (PXN/GRB2/FYN/RHOA) and Th17 cell differentiation (STAT1). These findings suggested that these five inflammatory genes may be important for AIS.

### Construction and functional analysis of the ceRNA network

Based on four miRNA databases (miRcode, starBase, DIANA-LncBase and miRwalk), 9 DEMs (hsa-let-7i, hsa-miR-125a, hsa-miR-1283, hsa-miR-19a, hsa-miR-345-5p, hsa-miR-4667-5p, hsa-miR-5100, hsa-miR-551a and hsa-miR-99b), were predicted to interact with 4 DELs (ITPK1-AS1, LINC01089, MCM3AP-AS1 and HCG27), which constituted 29 interaction pairs. Subsequently, 7,995 regulatory pairs between 9 DEMs, and 712 DEGs were detected in the miRwalk database, which was used for constructing the ceRNA network following integration with the DEM-DEL interacting relationships (data not shown).

Furthermore, the mRNAs in the ceRNA regulatory network were enriched in 66 KEGG signaling pathways, and 53 overlapped with the 191 AIS-associated KEGG pathways collected from the CTD database. The 436 genes enriched in these 53 KEGG pathways were subsequently extracted to construct a potential AIS-related ceRNA network ([Fig. 5](#f5-mmr-22-04-3081){ref-type="fig"}). In this network, the five inflammatory genes (PXN, FYN, STAT1, RHOA, GRB2) were included. Downregulated FYN was predicted to be regulated by upregulated hsa-miR-125a, whereas downregulated MCM3AP-AS1 and LINC01089 could also interact with hsa-miR-125a, thus forming the MCM3AP-AS1/LINC01089/hsa-miR-125a/FYN ceRNA axis ([Fig. 6](#f6-mmr-22-04-3081){ref-type="fig"}). Furthermore, the upregulated expression of RHOA, GRB2 and STAT1 was predicted to be regulated by the downregulated expression of hsa-let-7i, and this miRNA could also interact with the upregulated lncRNA, ITPK1-AS1. Accordingly, the ITPK1-AS1/hsa-let-7i/RHOA/GRB2/STAT1 ceRNA axes may also be important for AIS. Additionally, the upregulated expressions of PXN and HCG27 could interact with hsa-miR-19a to establish the HCG27/hsa-miR-19a/PXN ceRNA axis for AIS ([Fig. 6](#f6-mmr-22-04-3081){ref-type="fig"}). Notably, to the best of our knowledge this is the first time that the LncRNADisease database has shown that the lncRNAs involved in these ceRNA networks are associated with AIS, which suggested that they may be newly identified targets for the diagnosis and treatment of AIS. These five genes participated in 34 significant KEGG pathways ([Table V](#tV-mmr-22-04-3081){ref-type="table"}), 26 of which were similar to the results of module 7, including Th17 cell differentiation (STAT1), T cell receptor signaling pathway (FYN/GRB2/RHOA), chemokine signaling pathway (GRB2/RHOA/STAT1/PXN), and focal adhesion (FYN/GRB2/RHOA/PXN). Therefore, the lncRNA ceRNA axes associated with these five inflammatory DEGs may be of interest.

Discussion
==========

Extensive evidence indicates that AIS is commonly associated with the activation of immune-inflammatory responses, which leads to the increased expression of various pro-inflammatory cytokines, such as interleukin (IL)-6, IL-1 and C-reactive protein, and, subsequently, neuronal cell death ([@b25-mmr-22-04-3081],[@b26-mmr-22-04-3081]). It has been revealed through several *in vitro* and *in vivo* studies that lncRNAs involved in the inflammatory process may be potential targets for the diagnosis and treatment of AIS ([@b27-mmr-22-04-3081]--[@b31-mmr-22-04-3081]). For example, Zhang *et al* ([@b28-mmr-22-04-3081]) discovered that lncRNA-1810034E14Rik is significantly decreased in oxygen-glucose deprivation-induced microglial cells and in transient middle cerebral artery occlusion (MCAO) mice, and that 1810034E14Rik overexpression decreases the infarct volume and alleviates the neuronal damage by reducing the expression of pro-inflammatory cytokines IL-1β, tumor necrosis factor (TNF)-α and IL-6. Wang *et al* ([@b29-mmr-22-04-3081]) reported that levels of the lncRNA H19, increased in the plasma, white blood cells and brain of MCAO mice. Consequently, intracerebroventricular injection of H19 small interfering RNA reduced the infarct volume and brain edema through the suppressed release of pro-inflammatory IL-1β, TNF-α, and increased anti-inflammatory IL-10 secretion ([@b29-mmr-22-04-3081]). Similarly, *in vitro* experiments demonstrated that H19 knockdown attenuated brain tissue loss and neurological deficits by blocking M1 microglial polarization, and the production of TNF-α. Genetic knockdown of the lncRNAs metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and Maclpil, attenuated inflammatory injuries attained in MCAO mice ([@b30-mmr-22-04-3081],[@b31-mmr-22-04-3081]), and rare lncRNAs (ANRIL and H19) are associated with inflammation in patients with AIS ([@b7-mmr-22-04-3081],[@b29-mmr-22-04-3081],[@b32-mmr-22-04-3081]). In the present study, high-throughput datasets of patients with AIS were used to identify four crucial lncRNAs (MCM3AP-AS1, LINC01089, ITPK1-AS1 and HCG27) that may regulate T cell receptor signaling pathway genes (FYN, GRB2 and RHOA), and inflammatory chemokine signaling pathway genes (GRB2, RHOA, STAT1 and PXN) by functioning as ceRNAs that competitively bind with miRNAs. Previous studies have cited cancer-related functions for MCM3AP-AS1, LINC01089 and ITPK1-AS1 ([@b33-mmr-22-04-3081]--[@b36-mmr-22-04-3081]), but none has associated them with the pathogenesis of AIS, indicating that they may serve as novel, non-invasive biomarkers for the diagnosis and treatment of AIS. However, although HCG27 has been reported to be downregulated in IS ([@b11-mmr-22-04-3081]), the present study found it to be upregulated, which may be attributed to the difference in the sample selection (chronic vs. acute) and the number of patients (3 vs. 39). Thus, the results presented in this study may be more realistic for AIS.

Although no direct evidence was provided in this study to demonstrate that these lncRNAs are involved in AIS, the association with AIS of their interactive miRNA-mRNA pairs indirectly suggests their role. For example, it had been reported that the expression of RhoA is increased in cerebral IS model mice ([@b37-mmr-22-04-3081]), and the use of RhoA inhibitors reduced neuronal cell apoptosis and improved neurobehavioral outcomes ([@b37-mmr-22-04-3081],[@b38-mmr-22-04-3081]). In patients with stroke, T cells exhibit high RhoA activity, which may mediate the secretion of interferon γ and IL-18 ([@b39-mmr-22-04-3081]). There is also a significant correlation between the amount of inflammation, as indicated by the number of CD11b^+^/Iba^+^ cells, and the amount of RhoA activation in nerves from *in vivo* rat stroke models ([@b40-mmr-22-04-3081]). Microarray analysis reveals an enhanced expression of GRB2 24 at 72 h following ischemia, which has been confirmed by ELISA ([@b41-mmr-22-04-3081],[@b42-mmr-22-04-3081]). In addition, IS induces STAT1 expression, which is an important mediator of pro-inflammatory cytokines, such as IL-1β and TNF-α, and STAT1 inhibition by silymarin ameliorated inflammation-mediated brain tissue injury ([@b43-mmr-22-04-3081]). Hsa-let-7i is decreased in patients with AIS ([@b14-mmr-22-04-3081],[@b38-mmr-22-04-3081]), and inversely correlated with NIHSS score at admission and infarct volume ([@b44-mmr-22-04-3081],[@b45-mmr-22-04-3081]). *In vitro* functional analysis demonstrated that hsa-let-7i might be involved in AIS by negatively regulating inflammatory cluster of differentiation (CD)86 signaling in T helper cells, and IL-8 signaling pathways ([@b45-mmr-22-04-3081]). Thus, ITPK1-ASI may be upregulated in AIS to further sequester hsa-let-7i and prevent it from inhibiting the expression of RHOA/GRB2/STAT-1, ultimately resulting in the upregulation of RHOA/GRB2/STAT1 in AIS.

Using a MCAO AIS model, Franciska *et al* ([@b46-mmr-22-04-3081]) revealed that PXN expression is upregulated, especially following 1 h of ischemia ([@b46-mmr-22-04-3081]), and jasminoidin and ursodeoxycholic acid may be effective treatments of focal cerebral ischemia-reperfusion injury through downregulating PXN ([@b47-mmr-22-04-3081]). Hsa-miR-19a is decreased in patients with AIS compared with control samples ([@b14-mmr-22-04-3081]), especially within small vessel stroke ([@b48-mmr-22-04-3081]), and this downregulated expression is hypothesized to serve a crucial role in the pathogenesis of stroke by triggering the increased expression of CD46, an important transmembrane protein that induces inflammation ([@b49-mmr-22-04-3081]). Thus, HCG27 may also be upregulated to sponge hsa-miR-19a, thus facilitating the upregulation of PXN by reducing the expression of hsa-miR-19a, and subsequently promoting inflammation, and the development of AIS.

Experimental studies have demonstrated that the genetic knockdown of FYN kinases may have a potential neuroprotective effect for IS by decreasing neuronal apoptosis, cerebral edema, and enhancing the rate of neurological recovery ([@b50-mmr-22-04-3081],[@b51-mmr-22-04-3081]). These findings suggest that FYN may be upregulated during the inflammatory processes of AIS. However, the microarray meta-analysis in the present study revealed that FYN was significantly downregulated in the blood of patients with AIS. This inconsistent conclusion may be attributed to the dual function of FYN in the inflammatory process, as FYN knockout mice have displayed significantly worse colitis compared with wild-type mice, which correlated with decreased IL-10 and increased IL-17 expression in splenocytes and the gut ([@b52-mmr-22-04-3081]).

Previously, circulating hsa-miR-125a was reported to be upregulated in patients with IS compared with healthy controls ([@b12-mmr-22-04-3081]). A set of circulating miRNAs (hsa-miR-125a-5p, hsa-miR-125b-5p and hsa-miR-143-3p) was demonstrated to have a high accuracy (90.0%), sensitivity (85.6%) and specificity (76.3%) in the diagnosis of patients with IS compared with healthy controls ([@b12-mmr-22-04-3081]). Maitrias *et al* ([@b53-mmr-22-04-3081]) detected that hsa-miR-125a was significantly overexpressed in stroke patients compared with patients with asymptomatic atherosclerotic carotid plaques. Moreover, Kumar and Nerurkar ([@b54-mmr-22-04-3081]) demonstrated that miR-125a-3p targets genes involved in modulating immune responses, including cyclooxygenase-2, interleukin 1 receptor type 1, IL-10 and C-C motif chemokine ligand 4, in mouse brains ([@b54-mmr-22-04-3081]). Accordingly, it was hypothesized that MCM3AP-AS1 and LINC01089, may be downregulated in AIS, and thus, are unable to sequester hsa-miR-125a and to suppress its inhibitory effects over PXN that contribute to its downregulation. Thus, triggering neuroinflammation in patients\' brains and AIS.

The present study has several limitations. Firstly, the sample size of each dataset was small, and additional high-throughput sequencing experiments with larger samples are required to confirm the conclusions. Secondly, the present study only preliminarily screened crucial lncRNA biomarkers for the diagnosis and treatment of AIS. Further clinical experiments, such as quantitative-PCR analysis, correlation analysis, and receiver operating characteristic analysis should be used to prove the diagnostic and prognostic values of the lncRNAs. Finally, the ceRNA mechanisms of DELs should be verified by dual-luciferase reporter assays, and knockout or overexpression *in vitro* and *in vivo*.

In conclusion, to the best of our knowledge, the present study is the first to identify several inflammatory related DELs, MCM3AP-AS1, LINC01089, ITPK1-AS1 and HCG27, that may serve as underlying biomarkers for the diagnosis and treatment of AIS. These DELs may function as a ceRNA network (MCM3AP-AS1/LINC01089/hsa-miR-125a/FYN, ITPK1-AS1/hsa-let-7i/RHOA/GRB2/STAT1 and HCG27/hsa-miR-19a/PXN) to induce the development of AIS.
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![Hierarchical clustering heat map for the differentially expressed mRNAs in acute ischemic stroke. Data were obtained from datasets in the Gene Expression Omnibus database. On the horizontal axis, the white box indicates the control samples, and the black box represents the acute ischemic stroke samples. The vertical axis indicates the gene expression level. Red, high expression; blue, low expression.](MMR-22-04-3081-g00){#f1-mmr-22-04-3081}

![Venn diagram of the common DEMs. DEMs were identified in at least two expression profile datasets out of four for miRNAs in acute ischemic stroke (accession nos. GSE95204, GSE86291, GSE55937, and GSE110993), and were either (A) downregulated or (B) upregulated. DEM, differentially expressed microRNA.](MMR-22-04-3081-g01){#f2-mmr-22-04-3081}

![Functional enrichment analysis for the differentially expressed genes. (A) Top 30 significant GO terms. (B) Top 10 significant KEGG pathways. KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, gene ontology.](MMR-22-04-3081-g02){#f3-mmr-22-04-3081}

![A significant module that includes hub genes identified in the protein and protein interaction network for the differentially expressed genes in acute ischemic stroke. Blue, downregulated; red, upregulated. PXN, paxillin; RAF1, Raf-1 proto-oncogene serine/threonine kinase; TLR2, toll-like receptor 2; RPS6KA5, ribosomal protein S6 kinase A5; ITGA2B, integrin subunit α 2b; PRKCQ, protein kinase C θ; IL-1B, interleukin 1β; CBL, Cbl proto-oncogene; ZAP70, ζ chain of T cell receptor-associated protein kinase 70; TPM1, tropomyosin 1; PAK1, p21 (RAC1) activated kinase 1; RHOC, ras homolog family member C; ITGB5, integrin subunit β5; PAK2, p21 (RAC1) activated kinase 2; GRB2, growth factor receptor bound protein 2; PIK3AP1, phosphoinositide-3-kinase adaptor protein 1; FYN, FYN Proto-oncogene tyrosine-protein kinase; TPM2, tropomyosin 2; STAT1, signal transducer and activator of transcription 1; PTGS2, prostaglandin-endoperoxide synthase 2; FGR, FGR proto-oncogene Src family tyrosine kinase; ITPR3, inositol 1,4,5-trisphosphate receptor type 3; SYK, spleen-associated tyrosine kinase; HCK, HCK proto-oncogene Src family tyrosine kinase; RPS6KA3, ribosomal protein S6 kinase A3; CD79B, CD79b molecule; MAP4K1, mitogen-activated protein kinase kinase kinase kinase 1; CREB1, cAMP responsive element binding protein 1; SLA, Src-like adaptor; ITK, IL2 inducible T cell kinase; RHOA, Ras homolog family member A.](MMR-22-04-3081-g03){#f4-mmr-22-04-3081}

![Competing endogenous RNAs interaction network of all potential acute ischemic stroke-related long noncoding RNA/miRNA/mRNA axes. Blue, long noncoding RNAs; green, mRNA; red, microRNA. Hub genes are presented in red boxes. miR/miRNA, microRNA; PXN, paxillin; GRB2, growth factor receptor bound protein 2; FYN, FYN Proto-oncogene tyrosine-protein kinase; STAT1, signal transducer and activator of transcription 1; RHOA, Ras homolog family member A.](MMR-22-04-3081-g04){#f5-mmr-22-04-3081}

![Competing endogenous RNA interaction network between five inflammatory differentially expressed hub genes, and their related long noncoding RNA/miRNA axes in AIS. Purple, hub genes; red, microRNAs; green, long non-coding RNAs. miR/miRNA, microRNA; PXN, paxillin; GRB2, growth factor receptor bound protein 2; FYN, FYN Proto-oncogene tyrosine-protein kinase; STAT1, signal transducer and activator of transcription 1; RHOA, Ras homolog family member A.](MMR-22-04-3081-g05){#f6-mmr-22-04-3081}

###### 

Differentially expressed RNAs identified in patients with acute ischemic stroke from datasets in the Gene Omnibus database repository.

                        Dataset accession number                                                                                           
  --------------------- -------------------------- ------------- ------- ------------- ------- ------------- ------- ------------- ------- -------------
  MicroRNA                                                                                                                                 
    hsa-miR-99b         1.06                       2.14×10^−6^                                               0.77    1.69×10^−3^           
    hsa-miR-551a                                                 0.43    3.40×10^−2^                         0.15    2.13×10^−2^           
    hsa-miR-1263                                                 1.84    3.57×10^−3^                         0.42    3.95×10^−2^           
    hsa-miR-125a        1.30                       8.51×10^−8^                                               0.38    4.60×10^−2^           
    hsa-miR-1283        1.57                       2.59×10^−2^   3.38    3.94×10^−3^                                                       
    hsa-miR-19a         −1.00                      9.96×10^−3^                                               −0.54   3.55×10^−2^           
    hsa-let-7i          −1.05                      4.97×10^−4^                                               −0.54   3.96×10^−2^           
    hsa-miR-345-5p      −0.67                      2.53×10^−2^                         −0.35   1.66×10^−2^                                 
    hsa-miR-5100                                                 −0.85   3.54×10^−2^   −1.87   6.54×10^−3^                                 
    hsa-miR-4667-5p                                              −1.81   3.73×10^−2^   −0.41   2.74×10^−2^                                 
  Long non-coding RNA                                                                                                                      
    HCG27                                                                                                                          0.52    2.41×10^−4^
    ITPK1-AS1                                                                                                                      0.39    3.71×10^−2^
    MCM3AP-AS1                                                                                                                     −0.43   6.69×10^−8^
    LRRC37A4P                                                                                                                      −0.38   1.25×10^−3^
    LINC01089                                                                                                                      −0.34   6.05×10^−5^
  mRNA                                                                                                                                     
    PXN                                                                                                                            0.46    3.15×10^−4^
    FYN                                                                                                                            −0.53   1.19×10^−5^
    RHOA                                                                                                                           0.47    2.66×10^−6^
    STAT1                                                                                                                          0.54    1.14×10^−4^
    GRB2                                                                                                                           0.38    6.20×10^−3^

FC, fold change; miR, microRNA; ITPK1-AS1, inositol-tetrakisphosphate 1-kinase-antisense RNA 1; HCG27, human leukocyte antigen complex group 27; MCM3AP-AS1, minichromosome maintenance complex component 3 associated protein-antisense RNA 1; LRRC37A4P, leucine rich repeat containing 37 member A4; LINC01089, long intergenic non-protein coding RNA 1089; PXN, paxillin; FYN, FYN Proto-oncogene tyrosine-protein kinase; RHOA, Ras homolog family member A; GRB2, growth factor receptor bound protein 2.

###### 

Centralities analysis of the top 20 hub genes identified in the protein-protein interaction network from differentially expressed genes in acute ischemic stress.

  Gene     Degree centrality   Gene     Betweenness centrality   Gene     Closeness centrality
  -------- ------------------- -------- ------------------------ -------- ----------------------
  STAT3    96                  HDAC1    0.066077                 STAT3    0.39361
  RHOA     89                  BCL2     0.065222                 MAPK14   0.384987
  FYN      85                  STAT3    0.062793                 BCL2     0.383381
  MAPK14   80                  RHOA     0.056532                 CREBBP   0.38289
  CREBBP   79                  ACTB     0.050714                 FOS      0.381667
  BCL2     72                  CREBBP   0.049029                 RHOA     0.380331
  CDC42    71                  CDC42    0.047746                 MAPK1    0.377329
  HDAC1    71                  MAPK14   0.041837                 STAT1    0.376734
  STAT1    71                  FYN      0.040107                 MAPK3    0.375196
  MAPK1    71                  STAT1    0.036472                 FYN      0.369855
  FOS      71                  NOTCH1   0.035509                 NOTCH1   0.36724
  MAPK3    66                  FOS      0.034142                 ACTB     0.366564
  GRB2     61                  HIF1A    0.033411                 HDAC1    0.363443
  ACTB     58                  GRB2     0.030588                 PTEN     0.363332
  NOTCH1   53                  MAPK1    0.029564                 CDC42    0.362891
  TLR4     49                  GSK3B    0.023502                 GSK3B    0.362891
  PXN      49                  PTEN     0.023476                 PXN      0.362121
  GSK3B    47                  MAPK3    0.020408                 TLR4     0.360265
  HIF1A    47                  TLR4     0.019773                 GRB2     0.360048
  PTEN     47                  PXN      0.013521                 HIF1A    0.35929

STAT3, signal transducer and activator of transcription 3; RHOA, Ras homolog family member A; FYN, FYN Proto-oncogene tyrosine-protein kinase; MAPK14, mitogen-activated protein kinase 14; CREBBP, CREB binding protein; BCL2, BCL2 apoptosis regulator; CDC42, cell division cycle 42; HDAC1, histone deacetylase 1; STAT1, signal transducer and activator of transcription 1; MAPK1, mitogen-activated protein kinase 1; FOS, Fos proto-oncogene AP-1 transcription factor subunit; MAPK3, mitogen-activated protein kinase 3; GRB2, growth factor receptor bound protein 2; ACTB, actin β; NOTCH1, notch receptor 1; TLR4, toll-like receptor 4; PXN, paxillin; GSK3B, glycogen synthase kinase 3 β; HIF1A, hypoxia inducible factor 1 subunit α; PTEN, phosphatase and tensin homolog.

###### 

Significant modules extracted from the protein-protein interaction network of differentially expressed genes in acute ischemic stress.

  Module   Molecular complex detection score   Number of nodes   Number of edges   Genes
  -------- ----------------------------------- ----------------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1        31.632                              39                601               RPS5, EIF3D, SSR1, RPL36, EIF3G, EIF4B, RPL8, CASC3, SRP14, SSR2, RPS23, RNPS1, RPS9, RPL13, MRPS12, MRPL11, EIF3F, RPL4, RPS15A, IMP3, RPLP0, RPS2, RPL3, RPL9, RPSA, RPL22, UPF2, ETF1, MRPL24, RPL12, EIF3A, RPS4X, RPL10A, UPF3A, RPL13A, SRPRB, RPS3, RPL17, RPS15
  2        26.000                              26                325               HEBP1, CCR7, ANXA1, APP, CXCR5, CCL5, CXCL16, CXCR1, PPBP, CCR1, PNOC, C3AR1, FPR1, S1PR1, CXCR2, P2RY13, LPAR5, S1PR5, FPR2, GPR18, C5AR1, S1PR3, RGS18, GNAI3, LPAR2, ADRA2C
  3        12.308                              14                80                OASL, IFI27, STAT2, EEF1G, MX2, RNASEL, ADAR, GBP2, IFIT1, IFIT3, IFIT2, MX1, IFITM3, OAS1
  4        10.000                              10                45                NDUFB7, NDUFB3, NDUFB2, NDUFB11, NDUFB8, NDUFS8, NDUFV1, NDUFA12, NDUFS5, NDUFA11
  5        8.286                               36                145               P2RY10, RGS2, TBL1X, MED10, CDK4, VWF, SMARCD3, F13A1, GPR65, SERPING1, MED13L, CD8A, PROK2, F2RL1, CD3D, PTAFR, CEBPB, LTB4R, CD36, VEGFB, NCOA1, CD8B, SERPINA1, HLA-DRB1, CD3E, CD247, F5, CDK19, NCOA3, KLF4, PROS1, ACTN1, CEBPD, HELZ2, CEBPA, CD3G
  6        8.000                               8                 28                STAG2, B9D2, TAOK1, RAD21, CLIP1, NDEL1, AHCTF1, MIS12
  7        7.677                               32                119               PXN, RAF1, TLR2, RPS6KA5, ITGA2B, PRKCQ, IL1B, CBL, ZAP70, TPM1, PAK1, RHOC, ITGB5, PAK2, GRB2, PIK3AP1, FYN, TPM2, STAT1, PTGS2, FGR, ITPR3, SYK, HCK, RPS6KA3, CD79B, MAP4K1, CREB1, SLA, ITK, RHOA, CD19

###### 

KEGG pathway enrichment analysis for module 7 identified from the protein-protein interaction networks of differentially expressed genes in acute ischemic stroke.

  KEGG ID    Description                                                                 P-value adjusted   Gene
  ---------- --------------------------------------------------------------------------- ------------------ ----------------------------------------------------
  hsa04660   T cell receptor signaling pathway                                           1.29×10^−8^        RAF1/PRKCQ/ZAP70/PAK1/PAK2/GRB2/FYN/ITK/RHOA
  hsa04625   C-type lectin receptor signaling pathway                                    2.78×10^−7^        RAF1/IL1B/PAK1/STAT1/PTGS2/ITPR3/SYK/RHOA
  hsa04062   Chemokine signaling pathway                                                 1.19×10^−6^        PXN/RAF1/PAK1/GRB2/STAT1/FGR/HCK/ITK/RHOA
  hsa04510   Focal adhesion                                                              1.19×10^−6^        PXN/RAF1/ITGA2B/PAK1/ITGB5/PAK2/GRB2/FYN/RHOA
  hsa05205   Proteoglycans in cancer                                                     1.19×10^−6^        PXN/RAF1/TLR2/CBL/PAK1/ITGB5/GRB2/ITPR3/RHOA
  hsa04662   B cell receptor signaling pathway                                           6.14×10^−6^        RAF1/GRB2/PIK3AP1/SYK/CD79B/CD19
  hsa05163   Human cytomegalovirus infection                                             3.26×10^−5^        PXN/RAF1/IL1B/GRB2/PTGS2/ITPR3/CREB1/RHOA
  hsa05152   Tuberculosis                                                                7.77×10^−5^        RAF1/TLR2/IL1B/STAT1/SYK/CREB1/RHOA
  hsa04151   PI3K-AKT signaling pathway                                                  7.98×10^−5^        RAF1/TLR2/ITGA2B/ITGB5/GRB2/PIK3AP1/SYK/CREB1/CD19
  hsa05167   Kaposi sarcoma-associated herpes virus infection                            8.02×10^−5^        RAF1/STAT1/PTGS2/ITPR3/SYK/HCK/CREB1
  hsa04380   Osteoclast differentiation                                                  1.09×10^−4^        IL1B/GRB2/FYN/STAT1/SYK/CREB1
  hsa04650   Natural killer cell mediated cytotoxicity                                   1.14×10^−4^        RAF1/ZAP70/PAK1/GRB2/FYN/SYK
  hsa04010   Mitogen activated protein kinase signaling pathway                          1.32×10^−4^        RAF1/RPS6KA5/IL1B/PAK1/PAK2/GRB2/RPS6KA3/MAP4K1
  hsa04810   Regulation of actin cytoskeleton                                            1.44×10^−4^        PXN/RAF1/ITGA2B/PAK1/ITGB5/PAK2/RHOA
  hsa04012   ErbB signaling pathway                                                      1.69×10^−4^        RAF1/CBL/PAK1/PAK2/GRB2
  hsa05165   Human papillomavirus infection                                              2.43×10^−4^        PXN/RAF1/ITGA2B/ITGB5/GRB2/STAT1/PTGS2/CREB1
  hsa04722   Neurotrophin signaling pathway                                              7.17×10^−4^        RAF1/RPS6KA5/GRB2/RPS6KA3/RHOA
  hsa04611   Platelet activation                                                         8.26×10^−4^        ITGA2B/FYN/ITPR3/SYK/RHOA
  hsa04664   Fc ε RI signaling pathway                                                   9.55×10^−4^        RAF1/GRB2/FYN/SYK
  hsa05170   Human immunodeficiency virus 1 infection                                    9.55×10^−4^        PXN/RAF1/TLR2/PAK1/PAK2/ITPR3
  hsa05211   Renal cell carcinoma                                                        9.55×10^−4^        RAF1/PAK1/PAK2/GRB2
  hsa05140   Leishmaniasis                                                               1.20×10^−3^        TLR2/IL1B/STAT1/PTGS2
  hsa04014   Ras signaling pathway                                                       1.42×10^−3^        RAF1/ZAP70/PAK1/PAK2/GRB2/RHOA
  hsa04072   Phospholipase D signaling pathway                                           1.45×10^−3^        RAF1/GRB2/FYN/SYK/RHOA
  hsa05161   Hepatitis B                                                                 2.10×10^−3^        RAF1/TLR2/GRB2/STAT1/CREB1
  hsa04360   Axon guidance                                                               3.06×10^−3^        RAF1/PAK1/PAK2/FYN/RHOA
  hsa04928   Parathyroid hormone synthesis, secretion and action                         3.53×10^−3^        RAF1/ITPR3/CREB1/RHOA
  hsa04659   Type 17 T helper 7 cell differentiation                                     3.54×10^−3^        PRKCQ/IL1B/ZAP70/STAT1
  hsa05206   MicroRNAs in cancer                                                         3.90×10^−3^        RAF1/RPS6KA5/TPM1/GRB2/PTGS2/RHOA
  hsa05203   Viral carcinogenesis                                                        4.22×10^−3^        PXN/GRB2/SYK/CREB1/RHOA
  hsa04370   Vascular endothelial growth factor signaling pathway                        6.55×10^−3^        PXN/RAF1/PTGS2
  hsa04270   Vascular smooth muscle contraction                                          6.71×10^−3^        RAF1/PRKCQ/ITPR3/RHOA
  hsa04915   Estrogen signaling pathway                                                  7.70×10^−3^        RAF1/GRB2/ITPR3/CREB1
  hsa05321   Inflammatory bowel disease                                                  8.00×10^−3^        TLR2/IL1B/STAT1
  hsa04917   Prolactin signaling pathway                                                 9.19×10^−3^        RAF1/GRB2/STAT1
  hsa04150   mTOR signaling pathway                                                      9.73×10^−3^        RAF1/GRB2/RPS6KA3/RHOA
  hsa04921   Oxytocin signaling pathway                                                  9.73×10^−3^        RAF1/PTGS2/ITPR3/RHOA
  hsa05100   Bacterial invasion of epithelial cells                                      4.16×10^−2^        PXN/CBL/RHOA
  hsa05220   Chronic myeloid leukemia                                                    1.06×10^−2^        RAF1/CBL/GRB2
  hsa04022   Cyclic GMP-Protein kinase G signaling pathway                               1.22×10^−2^        RAF1/ITPR3/CREB1/RHOA
  hsa05210   Colorectal cancer                                                           1.44×10^−2^        RAF1/GRB2/RHOA
  hsa04621   Nucleotide-binding oligomerization domain-like receptor signaling pathway   1.48×10^−2^        IL1B/STAT1/ITPR3/RHOA
  hsa04540   Gap junction                                                                1.48×10^−2^        RAF1/GRB2/ITPR3
  hsa04658   Type 1 and 2 T helper cell differentiation                                  1.64×10^−2^        PRKCQ/ZAP70/STAT1
  hsa04912   Gonadotropin-releasing hormone signaling pathway                            1.66×10^−2^        RAF1/GRB2/ITPR3
  hsa05215   Prostate cancer                                                             1.76×10^−2^        RAF1/GRB2/CREB1
  hsa05169   Epstein-Barr virus infection                                                1.98×10^−2^        TLR2/STAT1/SYK/CD19
  hsa04620   Toll-like receptor signaling pathway                                        2.03×10^−2^        TLR2/IL1B/STAT1
  hsa05020   Prion diseases                                                              2.18×10^−2^        IL1B/FYN
  hsa04024   Cyclic AMP signaling pathway                                                2.23×10^−2^        RAF1/PAK1/CREB1/RHOA
  hsa04670   Leukocyte transendothelial migration                                        2.26×10^−2^        PXN/ITK/RHOA
  hsa04725   Cholinergic synapse                                                         2.26×10^−2^        FYN/ITPR3/CREB1
  hsa04071   Sphingolipid signaling pathway                                              2.58×10^−2^        RAF1/FYN/RHOA
  hsa04926   Relaxin signaling pathway                                                   3.18×10^−2^        RAF1/GRB2/CREB1
  hsa04910   Insulin signaling pathway                                                   3.56×10^−2^        RAF1/CBL/GRB2
  hsa05162   Measles                                                                     3.58×10^−2^        TLR2/IL1B/STAT1
  hsa05418   Fluid shear stress and atherosclerosis                                      3.59×10^−2^        ITGA2B/IL1B/RHOA
  hsa05130   Pathogenic Escherichia coli infection                                       4.16×10^−2^        FYN/RHOA
  hsa05213   Endometrial cancer                                                          4.53×10^−2^        RAF1/GRB2
  hsa05160   Hepatitis C                                                                 4.54×10^−2^        RAF1/GRB2/STAT1
  hsa04630   Janus kinase-STAT signaling pathway                                         4.97×10^−2^        RAF1/GRB2/STAT1

KEGG, Kyoto Encyclopedia for Genes and Genomes.

###### 

KEGG pathways enriched with potential crucial genes in the AIS-relevant ceRNA network.

  KEGG ID    Description                                                                 P-value adjusted   Gene
  ---------- --------------------------------------------------------------------------- ------------------ ---------------------
  hsa05152   Tuberculosis                                                                2.15×10^−9^        RHOA/STAT1
  hsa04659   Th17 cell differentiation                                                   6.91×10^−8^        STAT1
  hsa04380   Osteoclast differentiation                                                  6.91×10^−8^        FYN/GRB2/STAT1
  hsa05140   Leishmaniasis                                                               2.94×10^−7^        STAT1
  hsa04660   T cell receptor signaling pathway                                           4.90×10^−7^        FYN/GRB2/RHOA
  hsa04658   Type 1 and 2 T helper cell differentiation                                  4.90×10^−7^        STAT1
  hsa05164   Influenza A                                                                 3.10×10^−6^        STAT1
  hsa04662   B cell receptor signaling pathway                                           1.84×10^−5^        GRB2
  hsa04621   Nucleotide-binding oligomerization domain-like receptor signaling pathway   3.66×10^−5^        RHOA/STAT1
  hsa05223   Non-small cell lung cancer                                                  2.35×10^−4^        GRB2
  hsa05169   Epstein-Barr virus infection                                                5.75×10^−4^        STAT1
  hsa04611   Platelet activation                                                         5.87×10^−4^        FYN/RHOA
  hsa05145   Toxoplasmosis                                                               6.37×10^−4^        STAT1
  hsa04062   Chemokine signaling pathway                                                 6.37×10^−4^        GRB2/RHOA/STAT1/PXN
  hsa05162   Measles                                                                     6.37×10^−4^        STAT1
  hsa04068   FoxO signaling pathway                                                      6.38×10^−4^        GRB2
  hsa05321   Inflammatory bowel disease                                                  1.32×10^−3^        STAT1
  hsa05221   Acute myeloid leukemia                                                      1.58×10^−3^        GRB2
  hsa04670   Leukocyte transendothelial migration                                        2.76×10^−3^        RHOA/PXN
  hsa04071   Sphingolipid signaling pathway                                              2.91×10^−3^        FYN/RHOA
  hsa04919   Thyroid hormone signaling pathway                                           4.31×10^−3^        STAT1
  hsa04650   Natural killer cell mediated cytotoxicity                                   5.16×10^−3^        FYN/GRB2
  hsa04664   Fc e RI signaling pathway                                                   5.21×10^−3^        FYN/GRB2
  hsa05133   Pertussis                                                                   7.11×10^−3^        RHOA
  hsa05160   Hepatitis C                                                                 7.12×10^−3^        GRB2/STAT1
  hsa05203   Viral carcinogenesis                                                        9.56×10^−3^        GRB2/RHOA/PXN
  hsa04722   Neurotrophin signaling pathway                                              1.11×10^−2^        GRB2/RHOA
  hsa04010   Mitogen activated protein kinase signaling pathway                          1.32×10^−2^        GRB2
  hsa05161   Hepatitis B                                                                 1.35×10^−2^        GRB2/STAT1
  hsa05205   Proteoglycans in cancer                                                     1.56×10^−2^        GRB2/RHOA
  hsa04370   Vascular endothelial growth factor signaling pathway                        1.85×10^−2^        PXN
  hsa04510   Focal adhesion                                                              2.22×10^−2^        FYN/GRB2/RHOA/PXN
  hsa05212   Pancreatic cancer                                                           2.82×10^−2^        STAT1
  hsa04915   Estrogen signaling pathway                                                  3.12×10^−2^        GRB2

KEGG, Kyoto Encyclopedia for Genes and Genomes.
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